Key result
Metabolic syndrome linked to ~65% higher fasting C-peptide and greater epicardial fat thickness vs controls.
Why the study?
Epicardial fat tissue is considered an independent cardiovascular risk factor, and the relationship between C-peptide levels and epicardial fat tissue thickness in patients with metabolic syndrome needed evaluation.
Does C-peptide level correlate with epicardial fat tissue thickness in patients with metabolic syndrome?
Case-Control (n=70)
No
Does C-peptide level correlate with epicardial fat tissue thickness in patients with metabolic syndrome?
Fasting C-peptide levels are elevated in metabolic syndrome and correlate with epicardial fat tissue thickness, suggesting a role in assessing cardiometabolic risk.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for C-peptide in metabolic syndrome risk assessment; observational data leave clinical utility and correlation unproven.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Erman et al. (2021) conducted a case-control in Metabolic syndrome (n=70). Metabolic syndrome vs. Healthy volunteers was evaluated on Fasting serum C-peptide levels (ng/ml) (p=<0.001). Metabolic syndrome was associated with higher fasting serum C-peptide levels and epicardial fat tissue thickness compared to healthy controls.
Synapse has enriched 10 related papers. Consider them for comparative context: